Reprogramming RNA to transform patients’ lives.

Current Beat

Mar | 31 | 2025
Press Release
Remix Therapeutics™ to Present at Stifel 2025 Virtual Targeted Oncology Forum
Watertown, Mass. (March 31, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on […]

REMaster™ Drug
Discovery Platform

Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.
Data Science
Identifying druggable high value targets
Biology &
Biomolecular Sciences
Functional target validation and multiplexed HTS assays
Medicinal &
Computational Chemistry
Compound identification and optimization from proprietary library
Join Us

Become a Remixer

Remix™ welcomes new people and perspectives to join us in pushing scientific boundaries to offer new hope to patients.

Contact

General Inquiry